• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
    All News #Library
    Biotech

    TG Therapeutics Completes Enrollment For BRIUMVI Phase 3 Trial

    GLOBENEWSWIRE

    Briumvi Cuts Relapse And MRI Activity In Active RMS Study

    GLOBENEWSWIRE

    TG Therapeutics Reveals BRIUMVI Data Presentations At AAN 2026

    GLOBENEWSWIRE

    Precision Biosciences Gets $7.5M From TG Therapeutics

    BUSINESSWIRE

    TG Therapeutics Presents BRIUMVI® Data In Multiple Sclerosis

    GLOBENEWSWIRE

    TG Therapeutics Announce Data Presentations for BRIUMVI

    GLOBENEWSWIRE

    TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial

    GLOBENEWSWIRE

    Ublituximab Ms Data To Debut At Ectrims 2025 With Tg Therapeutics

    PHARMAWEB

    TG to Present BRIUMVI® Data at 2025 European Sclerosis Meeting

    GLOBENEWSWIRE

    TG Begins Phase 3 Trial Enrollment for Subcutaneous BRIUMVI

    GLOBENEWSWIRE

    TG Therapeutics Announces Briumvi Data at 2025 MS Centers Meeting

    GLOBENEWSWIRE

    TG Therapeutics Announces Data Presentations for Briumvi

    GLOBENEWSWIRE

    TG Therapeutics presents Briumvi data at AAN 2025 Meeting

    GLOBENEWSWIRE

    TG Therapeutics Announces BRIUMVI Data at AAN 2025 Meeting

    GLOBENEWSWIRE

    TG Therapeutics Announces BRIUMVI Publications in Journals

    GLOBENEWSWIRE

    TG Therapeutics To Present Briumvi Data In MS At AAN 2025 Meeting

    GLOBENEWSWIRE

    TG Reports Q4 & FY24 Results, Provides Business Update

    GLOBENEWSWIRE

    TG Therapeutics Presents BRIUMVI® Data at ACTRIMS Annual Forum

    GLOBENEWSWIRE

    TG Therapeutics To Present Briumvi Data In MS At ACTRIMS Forum

    GLOBENEWSWIRE

    TG Therapeutics Ranked 1 Fastest-Growing on 2024 Deloitte Fast 500™

    GLOBENEWSWIRE

    TG Therapeutics Reports Q3 2024 Results, Raises BRIUMVI® Guidance

    GLOBENEWSWIRE

    New data of Briumvi Shows 92% Free From Progression After 5 Years

    GLOBENEWSWIRE

    New Briumvi Data Shows Rapid Infusions Well Tolerated

    GLOBENEWSWIRE

    TG Therapeutics Announces Data Presentations for Multiple Sclerosis

    GLOBENEWSWIRE

    TG Therapeutics Gets IND Clearance For Azer-Cel In Multiple Sclerosis

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.